|
The Foundation for Angelman Syndrome Therapeutics (FAST) and the Angelman Syndrome Foundation (ASF) continue to work collaboratively on advocacy related to AS. We have created a new tool for advocacy, signed a letter along with over 200 patient advocacy organizations regarding rare disease policy priorities to the Trump Administration, and are happy to share a way you can voice your concerns about threats to Medicaid.
If you’re traveling to Washington, DC for our AS Congressional Advocacy Day, be sure to book your hotel by February 11th!
Learn more:
|